1-6 of 6
Todd Devries, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Association of Baseline and Postinfusion Biomarkers with Safety and Efficacy Endpoints in Patients Treated with Orvacabtagene Autoleucel (orva-cel; JCARH125) in the Phase 1/2 Evolve Study (NCT03430011)

Julia Piasecki, BA, Todd Devries, PhD, Aditya Radhakrishnan, PhD, Yan Li, PhD, Mark Heipel, BS, Brian A. Fox, PhD, Valeria Beckett, MS, Mariana Cota Stirner, MD PhD, Kristin Conte, MPH, Thomas Doerr, MSc, Sham Mailankody, MBBS, Sandy W. Wong, MD, Philip L. McCarthy, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–3.
https://doi.org/10.1182/blood-2020-137786
Published: 2020
Journal Articles

Orvacabtagene Autoleucel (orva-cel; JCARH125): A Fully Human BCMA-Targeted Second-Generation CAR T Cell Product Characterized By a Predominant Central Memory Phenotype with High in Vitro and In Vivo Proliferative Potential and Sustained In Vivo Persistence

Lucrezia Colonna, PhD, Garnet Navarro, BS, Todd Devries, PhD, Valeria Beckett, MS, Anthony Amsberry, BS, Aditya Radhakrishnan, PhD, Julia Piasecki, BA, Mark Heipel, BS, Yan Li, PhD, Uma Kavita, PhD, Melissa G Works, PhD, Mirna Mujacic, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–12.
https://doi.org/10.1182/blood-2020-136748
Published: 2020
Journal Articles

JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)

Sham Mailankody, MBBS, Myo Htut, MD, Kelvin P. Lee, MD, William Bensinger, MD, Todd Devries, PhD, Julia Piasecki, BA, Safiyyah Ziyad, PhD, Michelle Blake, PhD, John Byon, MDPhD, Andrzej Jakubowiak, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 957.
https://doi.org/10.1182/blood-2018-99-113548
Published: 2018
Journal Articles

Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted CAR T Cell Product, JCAR017

Tanya Siddiqi, MD, Jeremy S. Abramson, MD MMSc, Daniel Li, PhD, William Brown, MAS, Todd Devries, PhD, Kedar Dave, PhD, Jacob Garcia, MD, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, Jon E. Arnason, MD, Michael Wang, BS, Andres Forero-Torres, MD, David G. Maloney, MD PhD, Tina Albertson, MD, Claire L Sutherland, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 193.
https://doi.org/10.1182/blood.V130.Suppl_1.193.193
Published: 2017
Journal Articles

Pharmacokinetic, Pharmacodynamic and Blood Analytes Associated with Clinical Response and Safety in Relapsed/Refractory Aggressive B-NHL Patients Treated with JCAR017

Mark Heipel, BSc, Jeffrey Smith, BA, William Brown, MAS, Mandana Karimi, MSc, Benhuai Xie, PhD, Daniel Li, PhD, Tina Albertson, MD, Jacob Garcia, MD, Todd Devries, PhD, Claire L Sutherland, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2835.
https://doi.org/10.1182/blood.V130.Suppl_1.2835.2835
Published: 2017
Journal Articles

Recombinant Interleukin-21 Plus Rituximab: Clinical Activity in a Phase 1, Dose-Finding Trial in Relapsed Low-Grade B Cell Lymphoma.

John M. Timmerman, MD, John C. Byrd, MD, David J. Andorsky, MD, Muriel F. Siadak, PA-C, Todd DeVries, PhD, Diana F. Hausman, MD, John M. Pagel, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 2577.
https://doi.org/10.1182/blood.V110.11.2577.2577
Published: 2007